Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites-Reference-Cited by-同舟云学术

Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites

Published:2016-12-19 Issue:3 Volume:45 Page:294-305
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Liu Hong,Michmerhuizen Melissa J.,Lao Yanbin,Wan Katty,Salem Ahmed Hamed,Sawicki James,Serby Michael,Vaidyanathan Srirajan,Wong Shekman L.,Agarwal Suresh,Dunbar Martin,Sydor Jens,de Morais Sonia M.,Lee Anthony J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference28 articles.

1. Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study;Agarwal;J Clin Pharmacol,2016

2. Agarwal SK Salem AH Danilov AV Hu B Puvvada S Gutierrez M Chien D Lewis LD Wong SL (2016 b) Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-hodgkin lymphoma. Br J Clin Pharmacol DOI: 10.1111/bcp.13175 [published ahead of print].

3. Leptin decreases apoptosis and alters BCL-2 : Bax ratio in clonal rodent pancreatic beta-cells

4. Davids MS Roberts A Seymour JF Pagel JM Kahl BS Wierda WG Puvvada S Kipps TJ Anderson MA Salem AH (2017) Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol DOI: 10.1200/JCO.2016.70.4320 [published ahead of print].

5. A phase 1b study of venetoclax (ABT 199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ 65 years and not eligible for standard induction therapy;DiNardo;Blood,2015

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients;British Journal of Haematology;2024-07-31

2. Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study;2024-07-19

3. Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method;Anti-Cancer Drugs;2024-07-08

4. Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation;Clinical Pharmacokinetics;2024-07

5. Evaluation and Optimization of a Microcavity Plate–Based Human Hepatocyte Spheroid Model for Predicting Clearance of Slowly Metabolized Drug Candidates;Drug Metabolism and Disposition;2024-05-22